Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is a difficult study to interpret. There have been many trials of this vaccine. The early trials looked fantastic and this one looks pretty good. However, the largest randomized phase 3 "ACT 4" trial showed no improvement in overall survival. My thoughts are that the vaccine helps some people, with minimal side effects. Not enough to be used by itself but might be part of the ultimate cocktail. Treatments like this would be perfect candidates for the conditional approval pathway we are working on.
Posted on: 03/16/2020
Click HERE to return to brain tumor news headlines